Equities researchers at HC Wainwright started coverage on shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a research note issued to investors on Tuesday. The firm set a “buy” rating on the stock.

A number of other analysts also recently commented on the company. Raymond James Financial Inc. initiated coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. Brean Capital reissued a “buy” rating and issued a $48.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, September 7th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Needham & Company LLC reissued a “buy” rating and issued a $45.00 price objective on shares of Aerie Pharmaceuticals in a research note on Tuesday, August 23rd. Finally, Cantor Fitzgerald boosted their price objective on Aerie Pharmaceuticals from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 15th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $47.56.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 34.12 on Tuesday. The firm’s market capitalization is $951.68 million. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $35.32. The firm has a 50-day moving average price of $20.33 and a 200-day moving average price of $16.95.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.02. On average, equities analysts expect that Aerie Pharmaceuticals will post ($2.77) earnings per share for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The shares were purchased at an average cost of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.77% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its position in shares of Aerie Pharmaceuticals by 24.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,025,000 shares of the company’s stock worth $24,624,000 after buying an additional 400,000 shares during the period. Jennison Associates LLC increased its position in shares of Aerie Pharmaceuticals by 0.6% in the second quarter. Jennison Associates LLC now owns 3,711,695 shares of the company’s stock worth $65,326,000 after buying an additional 21,505 shares during the period. Royal Bank of Canada increased its position in shares of Aerie Pharmaceuticals by 8.4% in the first quarter. Royal Bank of Canada now owns 102,553 shares of the company’s stock worth $1,247,000 after buying an additional 7,982 shares during the period. Deerfield Management Co. increased its position in shares of Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock worth $32,011,000 after buying an additional 1,824,607 shares during the period. Finally, Foresite Capital Management II LLC increased its position in shares of Aerie Pharmaceuticals by 28.6% in the first quarter. Foresite Capital Management II LLC now owns 949,372 shares of the company’s stock worth $11,544,000 after buying an additional 211,011 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.